Alteogen Inc.
196170
Rang in aandelen
#1839
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Aandeelprijs
$174.81
Marktkapitalisatie
$12.17B
Verandering (1 dag)
5.55%
Verandering (1 jaar)
-44.58%
Land
KR
Handel Alteogen Inc. (196170)
Categorie
Healthcare
Omzet van Alteogen Inc. (196170)
Omzet in Jun 2026 TTM: $175.65M
Volgens de laatste financiële rapporten van Alteogen Inc. bedraagt de huidige omzet van het bedrijf (TTM) $175.65M. In 2023 behaalde het bedrijf een omzet van $74.56M een stijging ten opzichte van de omzet in het jaar 2022, die $22.83M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Alteogen Inc. van 2012 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $175.65M | 151.07% |
| 2024 | $69.96M | -6.17% |
| 2023 | $74.56M | 226.63% |
| 2022 | $22.83M | -29.96% |
| 2021 | $32.59M | -16.60% |
| 2020 | $39.08M | 54.39% |
| 2019 | $25.31M | 105.68% |
| 2018 | $12.31M | 8.35% |
| 2017 | $11.36M | 100.10% |
| 2016 | $5.68M | 41.12% |
| 2015 | $4.02M | -37.51% |
| 2014 | $6.44M | 22.58% |
| 2013 | $5.25M | 41.14% |
| 2012 | $3.72M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 7,087.26% |
US
|
|
| $2.23B | 1,168.44% |
US
|
|
| $15.74B | 8,863.55% |
AU
|
|
| $6.02B | 3,328.04% |
NL
|
|
| - | - |
CH
|
